Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) is expected to post its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect Cyclacel Pharmaceuticals to ...

NiKang Therapeutics has concluded the first cohort dosing in the open-label Phase I trial of NKT3964 as a monotherapy for ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

The exact molecular functions of Polo-like kinase 1 (PLK1) in mitotic prophase are not fully understood. This study shows ...

Cyclin-dependent kinases (CDKs) are protein kinases involved in critical cellular processes, such as cell cycle or transcription, whose activity requires association with specific cyclin subunits.

Researchers from SRM Institute of Science and Technology, led by Dr. KN Aruljothi, have published a study in ExRNA ...

AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor as first-line ...

1 provide one explanation. The KSHV cyclin directs cellular cyclin-dependent kinase 6 (CDK6) to phosphorylate cellular Bcl-2, an inhibitor of apoptosis. Phosphorylation renders Bcl-2 unstable ...

Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.

Verzenio plus Faslodex improved progression-free survival in HR+/HER2– advanced breast cancer after CDK/6i failure, with a ...

Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial: New Haven, Connecticut Wednesday, March 12, 2025, 10:00 Hrs [IST] Arvinas, Inc., a clinic ...

Get Instant Summarized Text (Gist) Cyclin-dependent kinase 2 (CDK2) is identified as a potential target for cancer therapy, particularly in overcoming resistance to CDK4/6 inhibitors used in ...